ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit
WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq:PROK) (“ProKidney”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m. ET on Thursday, September 29, 2022, in New York, NY.
Related news for (PROK)
- Breaking News: MoBot’s Latest Update as of 09/11/25 10:00 AM
- Today’s Top Performers: MoBot’s Market Review 08/04/25 02:00 PM
- Today’s Top Performers: MoBot’s Market Review 08/04/25 01:00 PM
- ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
- MoBot’s Stock Market Highlights – 07/15/25 08:00 AM